Quinone oxidoreductase 1 is overexpressed in gastric cancer and associated with outcome of adjuvant chemotherapy and survival

Table 3 Univariate and multivariate analyses of prognostic factors in gastric cancer patient

Clinical factor		1Univariate			Multivariate
	P value	HR	95%CI	P value	HR	95%CI
Interval
Age (< 60/≥ 60)
	-	-	-	0.01	1.90	1.20-3.02
Gender (male/female)
	-	-	-	0.96	1.03	0.62-1.66
Tumor size (< 5/≥ 5 cm)
	< 0.001	1.75	1.10-2.87	0.40	1.00	0.76-2.25
Tumor location
Proximal		1 (Reference)			1 (Reference)
Body	0.67	1.13	0.65-1.94	0.82	1.06	0.59-1.95
Distal	0.09	0.7	0.43-1.15	0.11	0.69	0.41-1.19
Whole2	-	-	-	-	-	-
Tumor stage (III, IV/I, II)
	< 0.001	3.11	1.96-5.09	< 0.001	2.64	1.56-4.61
Histological differentiation
Well		1 (Reference)			1 (Reference)
Moderate	0.3	1.58	0.68-4.30	0.62	1.26	0.53-3.48
Poor	0.07	2.03	0.96-5.23	0.15	1.79	0.83-4.67
NQO1 (high/low)
	0.01	1.73	1.16-2.58	0.05	1.56	1.01-2.40

¹Adjusted for age and gender.

²Patients in whole were not included due to too few cases (n = 4). NQO1: Quinine oxidoreductase 1; CI: Confidence interval; HR: Hazard ratio.